Milestone Pharmaceuticals (MIST) Competitors $1.38 -0.01 (-0.72%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.02 (-1.81%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. TERN, RNAC, TSVT, ALMS, INZY, GLUE, PVLA, LFCR, TNGX, and GOSSShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Terns Pharmaceuticals (TERN), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Terns Pharmaceuticals Cartesian Therapeutics 2seventy bio Alumis Inozyme Pharma Monte Rosa Therapeutics Palvella Therapeutics Lifecore Biomedical Tango Therapeutics Gossamer Bio Milestone Pharmaceuticals (NASDAQ:MIST) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Does the MarketBeat Community favor MIST or TERN? Milestone Pharmaceuticals received 41 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 68.55% of users gave Milestone Pharmaceuticals an outperform vote while only 60.27% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMilestone PharmaceuticalsOutperform Votes8568.55% Underperform Votes3931.45% Terns PharmaceuticalsOutperform Votes4460.27% Underperform Votes2939.73% Which has more volatility & risk, MIST or TERN? Milestone Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MIST or TERN? 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, MIST or TERN? Milestone Pharmaceuticals has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M73.78-$59.69M-$0.78-1.77Terns PharmaceuticalsN/AN/A-$90.21M-$1.09-2.74 Do analysts recommend MIST or TERN? Milestone Pharmaceuticals presently has a consensus target price of $17.00, indicating a potential upside of 1,131.88%. Terns Pharmaceuticals has a consensus target price of $15.63, indicating a potential upside of 422.58%. Given Milestone Pharmaceuticals' higher possible upside, equities research analysts plainly believe Milestone Pharmaceuticals is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is MIST or TERN more profitable? Terns Pharmaceuticals' return on equity of -32.76% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -151.82% -49.85% Terns Pharmaceuticals N/A -32.76%-31.33% Does the media favor MIST or TERN? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Terns Pharmaceuticals and 3 mentions for Milestone Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.34 beat Milestone Pharmaceuticals' score of 0.36 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Terns Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMilestone Pharmaceuticals beats Terns Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.78M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-1.708.9226.8419.71Price / Sales73.78253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book2.766.466.794.50Net Income-$59.69M$143.98M$3.23B$248.18M7 Day Performance17.95%3.04%4.07%1.14%1 Month Performance36.63%7.44%12.52%15.20%1 Year Performance-19.77%-2.46%16.83%6.56% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals2.6759 of 5 stars$1.38-0.7%$17.00+1,131.9%-20.3%$73.78M$1M-1.7030Earnings ReportTERNTerns Pharmaceuticals4.0965 of 5 stars$3.15+9.4%$15.63+396.0%-49.6%$275.11MN/A-2.6740News CoveragePositive NewsGap DownRNACCartesian Therapeutics1.5333 of 5 stars$10.37+1.1%$42.50+309.8%-60.4%$269.14M$34.17M-0.2064News CoverageAnalyst RevisionTSVT2seventy bio1.5274 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440News CoverageALMSAlumis2.2008 of 5 stars$5.95+5.9%$24.86+317.8%N/A$265.38MN/A0.00N/AEarnings ReportTrading HaltedINZYInozyme Pharma2.8913 of 5 stars$3.99+1.0%$11.75+194.5%-16.5%$257.60MN/A-2.5650Earnings ReportHigh Trading VolumeGLUEMonte Rosa Therapeutics2.1842 of 5 stars$4.11+3.3%$15.50+277.1%-16.0%$252.81M$159.49M-2.2590Positive NewsGap UpPVLAPalvella Therapeutics3.8034 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AEarnings ReportAnalyst RevisionLFCRLifecore Biomedical1.2466 of 5 stars$6.71-2.6%$8.00+19.2%+11.7%$248.44M$130.31M-11.98690Analyst ForecastTNGXTango Therapeutics1.5872 of 5 stars$2.29+52.7%$12.33+438.6%-73.0%$248.22M$40.99M-1.9490High Trading VolumeGOSSGossamer Bio3.7735 of 5 stars$1.09+4.8%$7.75+611.0%+72.7%$247.67M$114.70M-3.41180Earnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies TERN Alternatives RNAC Alternatives TSVT Alternatives ALMS Alternatives INZY Alternatives GLUE Alternatives PVLA Alternatives LFCR Alternatives TNGX Alternatives GOSS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIST Stock Free MIST Stock Alerts